EUVIMEDEUVIMED entdecken
Crossref

A new strategy for Astragaloside IV in the treatment of diabetic kidney disease: Analyzing the regulation of ferroptosis and mitochondrial function of renal tubular epithelial cells

Jun Liu, Kang Yang, Linlan Zhou, Jingwei Deng, Guoyi Rong, Lipeng Shi, Xin Zhang, Jing Ren, Yudi Zhang, Wenfu Cao

International Immunopharmacology · 2024-11 · 141 · 112794

DOI: 10.1016/j.intimp.2024.112794 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Immunopharmacology, 2024-11. Verfasst von Jun Liu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Combination of Chinese and Western Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China; Ch…. Hauptthemen laut MEDLINE: Ferroptosis, Diabetic Nephropathies, Saponins, Triterpenes. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 54 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In China, the Astragalus membranaceus root is used to treat chronic kidney disease. Astragaloside IV (AS-IV), the primary bioactive compound, exhibits anti-inflammatory and antioxidative properties; however, its renoprotective mechanism in diabetic kidney disease (DKD) remains unclear. The study aimed to investigate the protective effects of AS-IV on DKD revealing the underlying mechanisms. We established an early diabetic rat model by feeding a high-fat diet and administering low-dose streptozotocin. Twelve weeks post-treatment, renal function was evaluated using functional assays, histological analyses, immunohistochemistry, western blotting, and transmission electron microscopy. HK-2 cells exposed to high glucose conditions were used to examine the effect of AS-IV on oxidative stress, iron levels, reactive oxygen species (ROS), and lipid peroxidation. Network pharmacology, proteomics, molecular docking, and molecular dynamics simulation techniques were employed to elucidate the role of AS-IV in DKD. The results revealed that AS-IV effectively enhanced renal function and mitigated disease pathology, oxidative stress, and ferroptosis markers in DKD rats. In HK-2 cells, AS-IV lowered the levels of lipid peroxides, Fe2+, and glutathione, indicating the repair of ferroptosis-related mitochondrial damage. AS-IV reduced mitochondrial ROS while enhancing mitochondrial membrane potential and ATP production, indicating its role in combating mitochondrial dysfunction. Overall, in silico analyses revealed that AS-IV interacts with HMOX1, FTH1, and TFR1 proteins, supporting its efficacy in alleviating renal injury by targeting mitochondrial dysfunction and ferroptosis. AS-IV may play a renoprotective role by regulating mitochondrial dysfunction and inhibiting. HMOX1/FTH1/TFR1-induced ferroptosis. Accordingly, AS-IV could be developed for the clinical treatment of DKD-related renal injury.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FerroptosisDiabetic NephropathiesSaponinsTriterpenesMitochondriaDiabetes Mellitus, ExperimentalKidney TubulesEpithelial CellsAnimalsHumansMaleRatsCell LineRats, Sprague-DawleyOxidative StressReactive Oxygen SpeciesMolecular Docking Simulation

Stichwörter der Autor:innen

Astragaloside IVDiabetic kidney diseaseFerroptosisHeme oxygenase 1Mitochondrial dysfunction

Substanzen

astragaloside ASaponinsTriterpenesReactive Oxygen Species

Autor:innen und Institutionen

  • Department of Combination of Chinese and Western Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China; Chongqing Key Laboratory of Traditional Chinese Medicine for Prevention…
  • College of Traditional Chinese Medicine, Chongqing Medical University, Chongqing 400016, China; Chongqing Key Laboratory of Traditional Chinese Medicine for Prevention and Cure of Metabolic Diseases, Chongqing 400016, C…
  • Beibei Hospital of Traditional Chinese Medicine, Chongqing, 400700,China. Electronic address: 2640008075@qq.com.
  • College of Traditional Chinese Medicine, Chongqing Medical and Pharmaceutical College,Chongqing 401331, China. Electronic address: 15320450137@163.com.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Liu, J., Yang, K., Zhou, L., Deng, J., Rong, G., Shi, L., Zhang, X., Ren, J., Zhang, Y., & Cao, W. (2024). A new strategy for Astragaloside IV in the treatment of diabetic kidney disease: Analyzing the regulation of ferroptosis and mitochondrial function of renal tubular epithelial cells. International Immunopharmacology, 141, 112794. https://doi.org/10.1016/j.intimp.2024.112794

Vancouver

Liu J, Yang K, Zhou L, Deng J, Rong G, Shi L, et al. A new strategy for Astragaloside IV in the treatment of diabetic kidney disease: Analyzing the regulation of ferroptosis and mitochondrial function of renal tubular epithelial cells. International Immunopharmacology. 2024;141:112794. doi:10.1016/j.intimp.2024.112794

BibTeX
@article{Liu2024,
  author = {Liu, Jun and Yang, Kang and Zhou, Linlan and Deng, Jingwei and Rong, Guoyi and Shi, Lipeng and Zhang, Xin and Ren, Jing and Zhang, Yudi and Cao, Wenfu},
  title = {A new strategy for Astragaloside IV in the treatment of diabetic kidney disease: Analyzing the regulation of ferroptosis and mitochondrial function of renal tubular epithelial cells},
  journal = {International Immunopharmacology},
  year = {2024},
  volume = {141},
  pages = {112794},
  doi = {10.1016/j.intimp.2024.112794}
}
Kostenlos starten →